Denali Therapeutics (DNLI) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 2.5% versus a loss of 8.3%. Over five years, TARS leads with a +192.0% price change compared with -59.0% for DNLI. Tarsus Pharmaceuticals is the larger company by market cap ($3.60 billion vs $2.96 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | TARS |
|---|---|---|
| Share price | $18.45 | $73.01 |
| Market cap | $2.96B | $3.60B |
| 1-day change | +1.37% | -6.00% |
| YTD return | +11.75% | -10.83% |
| 1-year return | +2.50% | -8.35% |
| 5-year return | -59.02% | +192.04% |
| Forward P/E | — | 339.58 |
| EPS (TTM) | $-1.72 | $-15.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $451.36M |
| Revenue growth (YoY) | — | +146.71% |
| Net income (latest FY) | $-512.54M | $-66.42M |
| Operating margin | — | -15.72% |
| Net margin | — | -14.72% |
| 52-week high | $27.30 | $91.53 |
| 52-week low | $15.34 | $53.89 |
| Distance from 52-week high | -32.42% | -20.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +94.15% | +41.68% |
| Average volume | 1.68M | 871.07K |
| Shares outstanding | 160.29M | 49.31M |
| Employees | 503 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed TARS by 10.8 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
DNLI vs TARS FAQ
Which is bigger, Denali Therapeutics or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.60B compared with $2.96B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, DNLI or TARS?
DNLI returned +2.50% over the past 12 months, compared with -8.35% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.